Patents by Inventor Ju-Yong Yoon

Ju-Yong Yoon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180287980
    Abstract: In one embodiment, systems and methods for preventing messages from being redistributed are provided. A social-networking system may receive instructions from a user to create a messaging campaign. The instructions may include a blocking instruction. The system may identify a target user of the social-networking system to whom to present a message associated with the messaging campaign and present the message to the target user. The system may receive from the target user an input associated with the presented message. The input may be configured to cause the message to be presented to one or more other users connected to the target user within a threshold degree of separation in a social graph. In response to the input from the target user, the system may determine that the message is associated with the blocking instruction and prevent the message from being presented to the one or more other users.
    Type: Application
    Filed: March 28, 2017
    Publication date: October 4, 2018
    Inventors: Dan Barak, Christopher Michael Day, Gregory Karl Nelson, Dean Jackson, John Stephen Ketchpaw, Ju Yong Yoon, James F. Geist, JR.
  • Patent number: 9150630
    Abstract: There are provided Idbf (inhibitor of Dvl and bone formation) which is a novel Dvl-binding protein that binds to Dvl to inhibit signal transduction carried out through the Wnt/?-catenin signaling pathway, a gene for coding for the same, the use thereof, and the use of an inhibitor of the Idbf. The Idbf was known to be expressed by activation of the Wnt/?-catenin signaling pathway and bind to Dvl to block signal transduction carried out through the Wnt/?-catenin signaling pathway. Therefore, the Idbf can be used in development of medicines for inhibiting the signal transduction carried out through the Wnt/?-catenin signaling pathway, and an Idbf inhibitor can be used in preparation of medicines for activating the signal transduction carried out through the Wnt/?-catenin signaling pathway.
    Type: Grant
    Filed: August 3, 2009
    Date of Patent: October 6, 2015
    Assignee: Industry-Academic Cooperation Foundation, Yonsei University
    Inventors: Kang-Yell Choi, Hyun-Yi Kim, Ju-Yong Yoon
  • Patent number: 8952060
    Abstract: Provided is a composition for preventing hair loss or promoting hair growth including valproic acid or a pharmaceutically acceptable salt thereof as an active ingredient. The composition may be applied to various industrial fields, including pharmaceutical, cosmetic and beauty aid industries.
    Type: Grant
    Filed: May 11, 2010
    Date of Patent: February 10, 2015
    Assignee: Amorepacific Corporation
    Inventors: Hyoung-Jun Kim, Won Seok Park, Hyun Ju Koh, Pil Joon Park, Su Na Kim, Kang-Yell Choi, Ju-Yong Yoon, Soung-Hoon Lee
  • Publication number: 20120065262
    Abstract: Provided is a composition for preventing hair loss or promoting hair growth including valproic acid or a pharmaceutically acceptable salt thereof as an active ingredient. The composition may be applied to various industrial fields, including pharmaceutical, cosmetic and beauty aid industries.
    Type: Application
    Filed: May 11, 2010
    Publication date: March 15, 2012
    Inventors: Hyoung-Jun Kim, Won Seok Park, Hyun Ju Koh, Pil Joon Park, Su Na Kim, Kang-Yell Choi, Ju-Yong Yoon, Soung-Hoon Lee
  • Publication number: 20110135652
    Abstract: There are provided Idbf (inhibitor of Dvl and Bone formation) which is a novel Dvl-binding protein that binds to Dvl to inhibit signal transduction carried out through the Wnt/?-catenin signaling pathway, a gene for coding for the same, the use thereof, and the use of an inhibitor of the Idbf. The Idbf was known to be expressed by activation of the Wnt/?-catenin signaling pathway and bind to Dvl to block signal transduction carried out through the Wnt/?-catenin signaling pathway. Therefore, the Idbf can be used in development of medicines for inhibiting the signal transduction carried out through the Wnt/?-catenin signaling pathway, and an Idbf inhibitor can be used in preparation of medicines for activating the signal transduction carried out through the Wnt/?-catenin signaling pathway.
    Type: Application
    Filed: August 3, 2009
    Publication date: June 9, 2011
    Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION YONSEI UNIVERSITY
    Inventors: Kang-Yell Choi, Hyun-Yi Kim, Ju-Yong Yoon